On 7 August 2025, the H Shares of Sunshine Lake Pharma Co., Ltd. (6887.HK, Lens) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx) by way of introduction. CBI is honored to participate in the due diligence work for this IPO Project.

Sunshine Pharma is a China-based company principally engaged in research and development, production and commercialization of pharmaceutical products. The Company focuses on innovative drugs and is also involved in modified new drugs, generic drugs and biosimilars in various area including oncology, chronic disease treatment and anti-infective products.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, suppliers and customers. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence, social media search and related company search. The due diligence project globally covered 15 countries and regions, including China, Hong Kong, Japan, Germany, Russia and Switzerland, etc.